The DOI matches its Crossref record.
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Open accessAbstract
Background: Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. Objective: To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. Method: This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation. Results: Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low‐dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration. Limitations: Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group. Conclusion: Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low‐level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Self-citationTwo Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
Rosmarin, D., Passeron, T., Pandya, A. G., Grimes, P., Harris, J. E., Desai, S. R., Lebwohl, M., Ruer-Mulard, M., Seneschal, J., Wolkerstorfer, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118828 · Cited by 316
Self-citationEmerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Qi, F., Liu, F., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790125 · Cited by 203
Metadata
- Authors
- Liu, L. Y., Strassner, J. P., Refat, M. A., Harris, J. E., & King, B. A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 77
- Issue
- 4
- Pages
- 675-682.e1
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2746940679
- Cited by
- 241
- References
- 0
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. https://app.cochat.ai/papers/10.1016/j.jaad.2017.05.043
- The paper
- Liu, L. Y., Strassner, J. P., Refat, M. A., Harris, J. E., & King, B. A. (2017). Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2017.05.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.